Hematologic ß-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity.
Cancer Res
; 72(18): 4744-52, 2012 Sep 15.
Article
en En
| MEDLINE
| ID: mdl-22805305
ABSTRACT
Cellular microtubules composed of α-ß-tubulin heterodimers that are essential for cell shape, division, and intracellular transport are valid targets for anticancer therapy. However, not all the conserved but differentially expressed members of the ß-tubulin gene superfamily have been investigated for their role in these settings. In this study, we examined roles for the hematologic isoform ß-tubulin VI and functional genetic variants in the gene. ß-tubulin VI was highly expressed in blood cells with a substantial interindividual variability (seven-fold variation in mRNA). We characterized DNA missense variations leading to Q43P, T274M, and R307H, and a rare nonsense variant, Y55X. Because variations in the hematologic target of microtubule-binding drugs might alter their myelosuppressive action, we tested their effect in cell lines stably expressing the different ß-tubulin VI full-length variants, finding that the T274M change significantly decreased sensitivity to paclitaxel-induced tubulin polymerization. Furthermore, patients treated with paclitaxel and carrying ß-tubulin VI T274M exhibited a significantly lower thrombocytopenia than wild-type homozygous patients (P = 0.031). Together, our findings define ß-tubulin VI as a hematologic isotype with significant genetic variation in humans that may affect the myelosuppresive action of microtubule-binding drugs. A polymorphism found in a tubulin isoform expressed only in hemapoietic cells may contribute to the patient variation in myelosuppression that occurs after treatment with microtubule-binding drugs.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Trombocitopenia
/
Tubulina (Proteína)
/
Paclitaxel
/
Microtúbulos
Límite:
Humans
Idioma:
En
Año:
2012
Tipo del documento:
Article